soleno
therapeutics
participate
fireside
chat
oppenheimer
fall
healthcare
life
sciences
medtech
summit
redwood
city
globe
newswire
soleno
therapeutics
soleno
nasdaq
slno
biopharmaceutical
company
developing
novel
therapeutics
treatment
rare
diseases
today
announced
anish
bhatnagar
chief
executive
officer
participate
fireside
chat
oppenheimer
fall
healthcare
life
sciences
medtech
summit
monday
september
pm
et
live
audio
webcast
replay
fireside
chat
available
investors
section
company
website
soleno
therapeutics
soleno
focused
development
commercialization
novel
therapeutics
treatment
rare
diseases
company
lead
candidate
diazoxide
choline
dccr
tablets
oral
tablet
treatment
syndrome
pws
currently
evaluated
phase
iii
clinical
development
program
information
please
visit
statements
press
release
contains
statements
within
meaning
section
securities
exchange
act
amended
statements
statements
historical
facts
contained
press
release
statements
including
statements
regarding
company
expectations
concerning
among
things
ability
receive
data
first
half
phase
iii
destiny
pws
impact
pandemic
operations
clinical
trial
cases
identify
statements
terms
may
expect
plan
anticipate
could
intend
target
project
contemplates
believes
estimates
predicts
potential
continue
negative
terms
similar
expressions
statements
speak
date
press
release
subject
number
risks
uncertainties
assumptions
including
risks
uncertainties
associated
market
conditions
well
risks
uncertainties
inherent
soleno
business
including
described
company
prior
press
releases
periodic
reports
files
sec
events
circumstances
reflected
company
statements
may
achieved
occur
actual
results
could
differ
materially
projected
statements
except
required
applicable
law
company
plan
publicly
update
revise
statements
contained
herein
whether
result
new
information
future
events
changed
circumstances
otherwise
corporate
contact
brian
ritchie
lifesci
advisors
llc
